Explore

Capbase

NK-One Therapeutics, Inc. — Funding, Investors & Profile — Capbase

Private

Private securities offering disclosed via SEC Form D.

Biotechnology

$290KSource: [SEC]Total raised

UndisclosedSource: [SEC]Last valuation

NK-One Therapeutics, Inc. filed a Form D notice of exempt offering with the SEC.

1 rounds

No investors recorded yet for NK-One Therapeutics, Inc..

Leadership

Michael ShineExecutive Officer · Chief Executive Officer and PresidentSince 2026Source: [SEC]

Marco PappagalloExecutive Officer · SecretarySince 2026Source: [SEC]

NK-One Therapeutics, Inc. has no recorded acquisitions.

Still private — no exit on record.

No diversity signals recorded yet for NK-One Therapeutics, Inc..

Data aggregated from SEC EDGAR, Wikidata, and community contributions. Spotted an error? Propose a change or report an issue.